Barclays raised the firm’s price target on 10x Genomics (TXG) to $15 from $13 and keeps an Overweight rating on the shares post the earnings report. The firm says the integration of Scale’s split-pool barcoding with Chromium’s droplet-based technology could give 10x “the best of both worlds.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG: